FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2045131569> ?p ?o ?g. }

• W2045131569 endingPage "S17" @default.
• W2045131569 startingPage "S12" @default.
• W2045131569 abstract "Several discrete strategies have been suggested to prevent or reduce microbial resistance to antimicrobials, including optimal use of the agents (also known as good stewardship); control, removal, or restriction of antimicrobials; use of antimicrobials in combination; and rotational or cyclic use of antimicrobials. The latter strategy is attractive because it periodically removes from the institutional environment certain classes or specific agents that could induce or select resistance. Hospitalwide studies of aminoglycoside substitution employed from the late 1970s through the early 1990s, although not originally intended to test cycling or rotation of aminoglycosides, serendipitously provided data that may be useful in designing future studies. In particular, one 10-year study at the Minneapolis Veterans' Affairs Medical Center (MVAMC) rotated amikacin and gentamicin use over cycles of 12 to 51 months' duration. Significantly reduced resistance to gentamicin was found when amikacin was used, but resistance to gentamicin returned with the first gentamicin recycle. This was followed by reintroduction of amikacin a second time with decreased resistance to gentamicin and, finally, a second reintroduction of gentamicin without resistance to it recurring. Thus, some evidence of proof of principal can be garnered, albeit subject to considerable criticism. Critical examination of the design of the aminoglycoside rotation study and the unforeseen pitfalls is provided as a 13-element guidance list for design of future rotational studies. Rotational usage practices are likely to be most appropriate for drugs active against gram-negative bacilli because of the wide choices available for rotation. Future availability of new agents active against resistant gram-positive organisms will present the opportunity to cycle these agents as vancomycin substitutes. Careful monitoring of clinical outcomes and resistance will be required. Multicenter controlled trials that follow carefully designed protocols are most likely to produce statistically significant and clinically meaningful results." @default.
• W2045131569 created "2016-06-24" @default.
• W2045131569 creator A5002008542 @default.
• W2045131569 date "2000-01-01" @default.
• W2045131569 modified "2023-10-16" @default.
• W2045131569 title "Antimicrobial Cycling: Lessons Learned From the Aminoglycoside Experience" @default.
• W2045131569 cites W1569236388 @default.
• W2045131569 cites W1988078159 @default.
• W2045131569 cites W2005736219 @default.
• W2045131569 cites W2014602107 @default.
• W2045131569 cites W2029487461 @default.
• W2045131569 cites W2041215841 @default.
• W2045131569 cites W2048674235 @default.
• W2045131569 cites W2060349216 @default.
• W2045131569 cites W2072347463 @default.
• W2045131569 cites W2149514362 @default.
• W2045131569 cites W2408664925 @default.
• W2045131569 cites W2422788052 @default.
• W2045131569 cites W2916044971 @default.
• W2045131569 cites W4231446457 @default.
• W2045131569 cites W4240318442 @default.
• W2045131569 doi "https://doi.org/10.1086/503168" @default.
• W2045131569 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10654630" @default.
• W2045131569 hasPublicationYear "2000" @default.
• W2045131569 type Work @default.
• W2045131569 sameAs 2045131569 @default.
• W2045131569 citedByCount "54" @default.
• W2045131569 countsByYear W20451315692012 @default.
• W2045131569 countsByYear W20451315692013 @default.
• W2045131569 countsByYear W20451315692014 @default.
• W2045131569 countsByYear W20451315692015 @default.
• W2045131569 countsByYear W20451315692017 @default.
• W2045131569 countsByYear W20451315692019 @default.
• W2045131569 countsByYear W20451315692020 @default.
• W2045131569 countsByYear W20451315692022 @default.
• W2045131569 crossrefType "journal-article" @default.
• W2045131569 hasAuthorship W2045131569A5002008542 @default.
• W2045131569 hasConcept C177713679 @default.
• W2045131569 hasConcept C2775832221 @default.
• W2045131569 hasConcept C2777427914 @default.
• W2045131569 hasConcept C2777787772 @default.
• W2045131569 hasConcept C4937899 @default.
• W2045131569 hasConcept C501593827 @default.
• W2045131569 hasConcept C71924100 @default.
• W2045131569 hasConcept C86803240 @default.
• W2045131569 hasConcept C89423630 @default.
• W2045131569 hasConcept C94665300 @default.
• W2045131569 hasConceptScore W2045131569C177713679 @default.
• W2045131569 hasConceptScore W2045131569C2775832221 @default.
• W2045131569 hasConceptScore W2045131569C2777427914 @default.
• W2045131569 hasConceptScore W2045131569C2777787772 @default.
• W2045131569 hasConceptScore W2045131569C4937899 @default.
• W2045131569 hasConceptScore W2045131569C501593827 @default.
• W2045131569 hasConceptScore W2045131569C71924100 @default.
• W2045131569 hasConceptScore W2045131569C86803240 @default.
• W2045131569 hasConceptScore W2045131569C89423630 @default.
• W2045131569 hasConceptScore W2045131569C94665300 @default.
• W2045131569 hasIssue "S1" @default.
• W2045131569 hasLocation W20451315691 @default.
• W2045131569 hasLocation W20451315692 @default.
• W2045131569 hasOpenAccess W2045131569 @default.
• W2045131569 hasPrimaryLocation W20451315691 @default.
• W2045131569 hasRelatedWork W1535976727 @default.
• W2045131569 hasRelatedWork W1983951379 @default.
• W2045131569 hasRelatedWork W2147530319 @default.
• W2045131569 hasRelatedWork W2405713811 @default.
• W2045131569 hasRelatedWork W2408534409 @default.
• W2045131569 hasRelatedWork W2414286405 @default.
• W2045131569 hasRelatedWork W2414357953 @default.
• W2045131569 hasRelatedWork W2469521153 @default.
• W2045131569 hasRelatedWork W2993238898 @default.
• W2045131569 hasRelatedWork W4249693897 @default.
• W2045131569 hasVolume "21" @default.
• W2045131569 isParatext "false" @default.
• W2045131569 isRetracted "false" @default.
• W2045131569 magId "2045131569" @default.
• W2045131569 workType "article" @default.